Cooperative but Distinct Early Co-Signaling Events Originate From ERBB2 and ERBB1 Receptors Upon Trastuzumab Treatment in Breast Cancer Cells

Oncotarget - United States
doi 10.18632/oncotarget.17686
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Akt Rescue in Cardiomyocytes but Not Breast Cancer Cells After Doxorubicin and Anti-erbB2 Treatment

2005English

AKT Signaling in ERBB2-amplified Breast Cancer

Pharmacology and Therapeutics
Pharmacology
2016English

Combining Lapatinib (GW572016), a Small Molecule Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, With Therapeutic Anti-ErbB2 Antibodies Enhances Apoptosis of ErbB2-overexpressing Breast Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

Combination Treatment With Grb7 Peptide and Doxorubicin or Trastuzumab (Herceptin) Results in Cooperative Cell Growth Inhibition in Breast Cancer Cells

British Journal of Cancer
Cancer ResearchOncology
2007English

Women With Early Breast Cancer to Be Tested for Trastuzumab Treatment

BMJ
2005English

Preexisting Oncogenic Events Impact Trastuzumab Sensitivity in ERBB2-amplified Gastroesophageal Adenocarcinoma

Journal of Clinical Investigation
Medicine
2014English

Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study

Oncologist
Cancer ResearchMedicineOncology
2013English

T-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells

Clinical Cancer Research
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy